Advertisement

Topics

Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

11:06 EDT 23 Jun 2017 | Reuters

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.

Original Article: Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

NEXT ARTICLE

More From BioPortfolio on "Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...